Larsen & Toubro Limited (LTOD)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 38.05 |
|---|---|
| 52-week range | 35.34 – 49.45 |
| Return, 1 month / 3 months | −5.1% / −3.8% |
| Return, 1 year / 3 years | −13.7% / +12.9% |
| Trend | Below its 200-day average |
| RSI (14) | 44 |
| Volatility (1 year) | 26.3% |
| Worst drawdown (1 year) | -24.8% |
| Average daily value traded | 0.36M USD |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Larsen & Toubro is an Indian engineering and construction group based in Mumbai. It builds large infrastructure such as roads, bridges, metro systems, ports and power plants, and supplies equipment for industry, energy and defence. Its customers include governments, utilities and private companies in India and abroad, and it also provides technology and engineering services through its subsidiaries. The company works across construction, manufacturing and services.
Larsen & Toubro Limited trades under the code LTOD on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Larsen & Toubro Limited (LTOD) trades on the London Stock Exchange in UK. It last closed at USD 38.05 on 27 October 2026.
Its price-based Market X-Ray is 43 out of 100 (a weak price profile), ranking 2,484 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 13.7% and over the last three months it fell 3.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 35 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -7.8% | ||
| From 52-week high | -21.9% | ||
| Momentum | 35 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -3.8% | ||
| 6-month return | -10.0% | ||
| 12-month return, skipping the last month | -9.0% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.8% | ||
| Liquidity | 43 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.36M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 21 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.5% |
|---|---|
| 1 month | −5.1% |
| 3 months | −3.8% |
| 6 months | −10.0% |
| 1 year | −13.7% |
| 3 years | +12.9% |
| 5 years | +61.3% |
Signals
| 50-day / 200-day average | 39.85 / 41.26 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.99 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 May 2026 | INR 0.3330 |
| 2 Jun 2025 | INR 0.3277 |
| 19 Jun 2024 | INR 0.2743 |
| 1 Aug 2023 | INR 0.0635 |
| 21 Jul 2022 | INR 0.2237 |
| 27 Jul 2021 | INR 0.1933 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.